THE 11th Sugiyama Laboratory Open Symposium

“Prediction of complex drug-drug interactions, pharmacogenomics and our attempts on virtual clinical studies”

Date : Feb 23 10:00-16:45, 2018

Place : RIKEN Yokohama Main Building Hall 


Registration Fee : Free

※Banquet will be held on the day before※
   Date:Thursday, 22 February, 18:00 - 19:55
   Venue:Cafeteria at Yokohama RIKEN
   Banquet fee: \ 3,000 -


Registration ; mail to  yslab.secretary [at] with below information.


 name/affiliation/mail address/banquet(attend or not)

※ no later than Jan 31st, 2017 Japan time


 This Symposium is a part of the RIKEN Symposium Series.


PDFファイル 179.1 KB

10:00-10:10 Opening remarks
                      Yuichi Sugiyama (Sugiyama Laboratory, RIKEN Innovation Center)

10:10-11:00  【Plenary lecture】
                      Applying Recent Advances in ADME Science to Enable Drug Design and Clinical                                       Development
                      Tremaine, Larry M (Pfizer Inc.)

11:00-11:35    Successes and challenges with small-molecule proteasome inhibitor drugs: Insights                              for their pharmacokinetics and strategies for moving forward
                       Wooin Lee (Seoul National University / RIKEN)

11:35-11:50    Break

11:50-12:25    Kinetic consideration of OATP contribution to drug disposition based on extended                          clearance concept: Insight to genetic and ethnic variability and drug-drug interaction
                       Yoshiko Tomita (Sumitomo Dainippon Pharma Co., Ltd.)

12:25-13:35    Lunch Break (70)

13:35-14:10    Comparative assessment of efficacy and safety of statins based on exposure-response                          relationship and approach to virtual clinical study.
                       Yuki Iwaki (Janssen Pharmaceutical Companies of Johnson & Johnson)

14:10-14:45    Predicting complex DDIs related to CYP induction and OATP inhibition by PBPK model of                           rifampicin with its own hepatic uptake and auto-induction
                       Ryuta Asaumi (Ono Pharmaceutical Co., Ltd.)

14:45-15:20    Application of PBPK modeling to renal OCT2 and MATEs mediated DDIs: Predicting                            changes in renal clearance and blood AUC caused by the transporter inhibitors
                       Kotaro Nishiyama (Nippon Boehringer Ingelheim Co., Ltd.)

15:20-15:40    Coffee Break

15:40-16:15    PBPK analysis of nonlinear pharmacokinetics of taxanes; Role of hepatic uptake                           transporters, plasma protein binding and pharmaceutical excipients
                       Nora Lee (Daewoong Pharmaceutical Co., Ltd. / RIKEN)

16:15-16:45    General Discussion
                       Yuichi Sugiyama (Sugiyama Laboratory, RIKEN Innovation Center)

Contact to:Sugiyama's Laboratory
Email: yslab.secretary [at]
Tel: 045‐503‐9210